NSABP

(redirected from National Surgical Adjuvant Breast and Bowel Project)
AcronymDefinition
NSABPNational Surgical Adjuvant Breast and Bowel Project (cancer treatment trial)
References in periodicals archive ?
Ongoing randomized, double-blind, placebo-controlled clinical trials, such as the National Surgical Adjuvant Breast and Bowel Project B-34, are expected to provide definitive answers as to whether prescribing bisphosphonates protects against bone metastases.
Two trials that could provide additional insights are the TARGIT (Targeted Intraoperative Radiation Therapy) trial in Europe and the National Surgical Adjuvant Breast and Bowel Project B-39/Radiation Therapy Oncology Group 0413 trial in the United States, Dr.
To develop a context-specific prognostic assay that addresses which women diagnosed with axillary node-negative and estrogen receptor-positive breast cancer require more than 5 years of tamoxifen therapy, National Surgical Adjuvant Breast and Bowel Project (NSABP) investigators have collaborated with scientists at Genomic Health, Inc, the developers of methods for high-throughput QRT-PCR with RNA extracted from FPETs.
The National Surgical Adjuvant Breast and Bowel Project (NSABP), funded by the US National Cancer Institute, randomized postmenopausal women to exemestane or placebo.
The Oncotype DX recommendation was based on 16 years of follow-up data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) trial NSABP 14, Dr.
validated this protocol in a subset of 651 patients in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 study [1].
That alert, still in effect, was based on what he deemed "rather unremarkable trends" toward an excess of recurrences with more than 5 years of therapy in roughly 1,000 participants in the National Surgical Adjuvant Breast and Bowel Project B-14 trial.
The National Surgical Adjuvant Breast and Bowel Project's (NSABP) P-1 study reported tamoxifen prevented 50% of estrogen receptor-positive breast cancers in high-risk women on tamoxifen therapy for 5 years (J.
The National Surgical Adjuvant Breast and Bowel Project (NSABP), a national network of cancer researchers, initiated the study known as B-14 in 1981 and accrued volunteers until 1988.
In the landmark National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial, in which more than 13,000 high-risk women were randomized to tamoxifen or placebo, rates of endometrial cancer, pulmonary emboli, deep-vein thrombosis, and stroke in patients younger than age 50 years weren't significantly different with tamoxifen versus placebo.
Tamoxifen substantially cuts the risk of invasive and noninvasive breast cancer, researchers confirmed in an extended follow-up of the National Surgical Adjuvant Breast and Bowel Project that was initially reported in 1998.
Directed by the National Surgical Adjuvant Breast and Bowel Project (NSABP), this study began in early 1992.
Full browser ?